Please assess the completion status of the following clinical trial:

Trial Title: Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 2 months old infants on the day of inclusion~* Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg~* Informed consent form signed by one or both parents or by the legally acceptable representative and 1 or 2 independent witnesses~* Able to attend all scheduled visits and to comply with all trial procedures~* Has complied with the national immunization calendar (BCG for both countries) for the first 2 months of life.~Exclusion Criteria:~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Subjects with congenital or acquired immunodeficiency in the child's surrounding~* Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood-derived products received since birth~* Any vaccination in the 4 weeks preceding the first trial vaccination~* Vaccination planned in the 4 weeks following the trial vaccination~* Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b or hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically)~* Mother known as seropositive for HIV or Hepatitis C, or known carrier of Hepatitis B surface antigen~* Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, or Haemophilus influenzae type b infection(s)~* Coagulopathy, thrombocytopenia or a bleeding disorder contraindicating IM vaccination~* History of seizures~* Febrile or acute illness on the day of inclusion.

- Gender: ALL
- Minimum Age: 50 Days
- Maximum Age: 71 Days
- Healthy Volunteers: t

Study Arms:
- Group 1: DTaP-IPV-Hep B-PRP-T (Type: EXPERIMENTAL): None
- Group 2: Tritanrix-Hep B/Hib™+OPV (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).